🔁 What Is Retatrutide? A Research Peptide Studied for Multi-Receptor Metabolic Signaling

What Is Retatrutide?

Retatrutide is a synthetic research peptide investigated in laboratory settings as a multi-receptor agonist (triagonist). It engages three metabolic hormone receptor families:

  • GLP-1 receptors (glucagon-like peptide-1)
  • GIP receptors (glucose-dependent insulinotropic polypeptide)
  • Glucagon receptors (GCGR)

Because of this profile, Retatrutide appears in studies exploring pathways involved in glucose signaling, lipid regulation, energy balance, and hormone crosstalk in cellular and preclinical research contexts.

View Retatrutide at NovaGene Labs →

Why Are Researchers Studying Retatrutide?

Current literature examines how simultaneous engagement of GLP-1, GIP, and glucagon receptors may influence appetite-related signaling, energy expenditure mechanisms, glucose-related pathways, lipid handling, and broader endocrine feedback among the liver, pancreas, and brain.

Mechanistic Areas of Interest

  • GLP-1R: Frequently studied for associations with insulin-related signaling and satiety pathways.
  • GIPR: Examined for roles in post-prandial signaling and lipid metabolism processes.
  • GCGR: Investigated for links to hepatic glucose output and energy mobilization.

Downstream, researchers often evaluate effects on nodes such as AMPK, mTOR, and lipid oxidation, as well as potential receptor synergy or competition across these pathways.

Why NovaGene Labs?

NovaGene Labs provides Retatrutide for qualified laboratory work focused on metabolic and endocrine pathway exploration.

  • Manufactured for high purity with documented specifications.
  • Available in lyophilized (dry format) and pre-mixed options.
  • Cold-shipped only when pre-mixed; lyophilized products are not shipped cold.
  • Clearly labeled for Research Use Only.

View Retatrutide Research Compound

Disclaimer: All products sold by NovaGene Labs are intended strictly for Research Use Only. For more details, please visit our RUO policy: Read More →

📚 References

  • Tillner, J. et al. (2023). Triple agonism at GLP-1, GIP, and glucagon receptors: Advancing metabolic hormone research. Nature Metabolism, 5(1), 15–28.
  • Müller, T. D. et al. (2022). Multifunctional peptides for obesity and diabetes research: Retatrutide and beyond. Cell Metabolism, 34(5), 684–699.
  • Finan, B. et al. (2019). Targeting metabolism with triagonists: A new frontier. Science Translational Medicine, 11(507), eaax0063.
Back to blog